Skip to main content
Premium Trial:

Request an Annual Quote

BD Bioscience, Moving Deeper Into High-content Cell Analysis, Licenses IP from Cellomics

NEW YORK, Nov. 9 (GenomeWeb News) - Cellomics has given Becton Dickinson's BD Bioscience division non-exclusive, worldwide rights to its core high content-screening patent portfolio, the firms said today.


The license gives BD Bioscience broad claims to Cellomics' HCS technology and "specific classes" of HCS assays, such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization, the companies said. 


BD Bioscience said the move is aimed at further positioning it into the area of high-content cellular analysis, emphasized by the company's acquisition of Atto Bioscience in July.


The Cellomics deal was also designed to bolster BD's capabilities in live cell research, which includes high-resolution imaging, flow cytometry, and reagent systems, Mark Lewis, vice president of BD Biosciences, said in a statement.


Financial details of the agreement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.